Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 116Carcinoma, Non-Small-Cell Lung 101Carcinoma, Renal Cell 67Colorectal Neoplasms 46Neoplasm Metastasis 40Squamous Cell Carcinoma of Head and Neck 38Carcinoma, Hepatocellular 38Neoplasms 35Lung Neoplasms 34Stomach Neoplasms 33Urinary Bladder Neoplasms 22Hodgkin Disease 20Carcinoma, Transitional Cell 20Brain Neoplasms 20Pancreatic Neoplasms 18Ovarian Neoplasms 18Prostatic Neoplasms 16Head and Neck Neoplasms 16Colonic Neoplasms 16Skin Neoplasms 15Sarcoma 14Glioblastoma 14Adenocarcinoma Of Esophagus 14Triple Negative Breast Neoplasms 13Carcinoma, Merkel Cell 13Small Cell Lung Carcinoma 12Rectal Neoplasms 12Esophageal Neoplasms 12Breast Neoplasms 12Uveal Melanoma 11

Interventions

durvalumab 2Gemcitabine 2titanium silicide 1regorafenib 1pembrolizumab 1Nivolumab 1Injections 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Biliary Tract Cancer × Nivolumab × 1 year × Clear all
NCT04172402 2025-07-22

NGS as the First-line Treatment in Advanced Biliary Tract Cancer

National Health Research Institutes, Taiwan

Phase 2 Completed
48 enrolled
Gastrointestinal

Advanced Biliary Tract Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡